Cholesterol embolization syndrome: A case report and literature review Authors: Xiaojie Zhang Published: 2026 ABSTRACT AbstractCholesterol embolization syndrome is a clinical condition caused by cholesterol crystals dislodged from atherosclerotic plaques, leading to distal arterial occlusion and subsequent organ ischemia. We present a case of a 61-year-old male who developed blue toe syndrome, reticular livedo, and gastrointestinal bleeding 1 week after aortic interventional therapy for intermittent claudication. The patient exhibited eosinophilia and multiorgan dysfunction. Diagnosis was confirmed by fundoscopic examination revealing a cherry-red spot at the macula. This case, combined with a literature review, discusses the clinical features, diagnostic criteria, and therapeutic strategies of this disease to enhance clinician awareness. The patient was followed for 3 months with ongoing follow-up thereafter, during which renal function partially recovered from stage 4 to stage 3b chronic kidney disease with conservative management.Keywords: Cholesterol embolization syndrome, Blue toe syndrome, Eosinophilia, Cherry-red spot, Case report Cholesterol embolization syndrome (CES), also known as cholesterol crystal embolization, atheroembolism, or blue toe syndrome, is a clinical syndrome caused by cholesterol crystals dislodged from atherosclerotic plaques, which migrate distally and occlude small arteries, leading to organ ischemia and necrosis. This condition was first described by Panum in 1862. The incidence of CES is estimated at 1% to 5%, though this may be an underestimate because of its diverse clinical manifestations and lack of specificity, leading to misdiagnosis or missed diagnosis. CES predominantly affects elderly males with a history of atherosclerosis. Precipitating factors include vascular interventional procedures, anticoagulation or thrombolytic therapy, and arterial trauma. The disease may involve multiple organ systems, including the skin, kidneys, gastrointestinal tract, and nervous system, with a mortality rate of 25% to 50%. Early diagnosis and treatment are crucial for improving outcomes. The patient provided written informed consent for publication of this case report and accompanying images. Case report A 61-year-old male presented with bilateral lower limb weakness and intermittent claudication for 1 month. His walking distance was less than 100 m (Rutherford category 3), significantly impairing his daily activities and quality of life. He had been on the best medical therapy for 3 months prior to intervention, including cilostazol 100 mg twice daily, high-intensity statin therapy (atorvastatin 40 mg daily), aspirin 100 mg daily, smoking cessation, and a structured supervised exercise program. However, his symptoms remained refractory to conservative management. Computed tomography angiography of the aorta and color Doppler ultrasonography of the lower extremity vessels revealed extensive atherosclerotic changes throughout the aorta (Fig 1, A) and left iliac artery atherosclerotic occlusion (Fig 1, B). Given the patient's young age (61 years) and the focal nature of the left iliac occlusion with good distal runoff, open surgical bypass was discussed at the multidisciplinary vascular conference. However, endovascular therapy was selected as the first-line approach because of its lower periprocedural morbidity, faster recovery, and the patient's preference after informed consent. A, Computed tomography angiography showing left iliac artery atherosclerotic occlusion and extensive aortic atherosclerotic changes. B, Left iliac artery atherosclerotic occlusion (digital subtraction angiography). C, Intraluminal plaque debulking of the left iliac artery was performed using a Rotarex mechanical atherectomy system (Straub Medical). The patient was admitted 1 day before the procedure for preoperative evaluation and hydration, given the presence of extensive aortic atherosclerosis and mild baseline renal dysfunction (serum creatinine, 112 μmol/L; estimated glomerular filtration rate [eGFR], 58 mL/min/1.73 m2). The procedure was performed via the left radial artery. After successful puncture, a 6F Terumo sheath was inserted. A 0.035-inch, 260-cm hydrophilic guidewire was advanced, and a pigtail angiographic catheter was introduced. Aortic arch angiography revealed an irregular aortic wall with filling defects. Under guidewire guidance, the pigtail catheter was repositioned to the descending and abdominal aorta; repeat angiography demonstrated extensive aortic atherosclerosis with rough vascular walls. The guidewire was reinserted, the pigtail catheter was withdrawn, and an 8F COOK Flexor 90-cm guiding sheath was advanced over the guidewire through the left subclavian artery, across the aortic arch, and down to the common iliac artery bifurcation. A 5F 125-cm MPA1 catheter and a 0.014-inch, 300-cm guidewire were used to cross the occluded left iliac artery through the true lumen. Intraluminal plaque debulking of the left iliac artery was performed using a Rotarex mechanical atherectomy system (Straub Medical) (Fig 1, C). During treatment, the distal 2 cm of the occlusion was preserved as a natural protective umbrella, and the device was advanced and withdrawn at 1 mm/s, with the final 2 cm treated in the same manner. Postatherectomy angiography demonstrated satisfactory lumen gain (approximately 50%) with patent flow. The residual stenosis was then dilated with a Mustang balloon catheter (10 mm/120 mm; Boston Scientific). Repeat angiography showed residual stenosis greater than 30% in the left iliac artery, and a balloon-expandable covered stent (Lifestream 10 mm/120 mm; BD) was deployed in the stenotic segment. Final angiography confirmed a patent left iliac artery. The right common iliac artery had a short-segment stenosis that was treated by balloon angioplasty alone, with satisfactory luminal expansion. Intraoperative anticoagulation was achieved with intravenous heparin (100 U/kg bolus, activated clotting time >250 seconds maintained throughout the procedure). Recanalization was achieved intraluminally without subintimal passage; the procedure was technically straightforward and uneventful. The intervention was limited to the aortoiliac segment. Postprocedure, the patient remained hospitalized for 48 hours for hemodynamic monitoring, puncture site observation, and serial creatinine checks to monitor for contrast-induced nephropathy. No adverse events occurred during the index admission; the patient was ambulatory, pain free, and hemodynamically stable throughout. He was discharged 3 days postoperatively on a planned basis. He was prescribed oral aspirin enteric-coated tablets, 100 mg once daily; clopidogrel, 75 mg once daily; and rosuvastatin, 10 mg daily. One week postoperatively, the patient developed bilateral toe pain with blue discoloration (blue toe syndrome) (Fig 2, A), though peripheral limb temperature was maintained. Concurrent reticular livedo was observed on the bilateral lower extremity skin (Fig 2, B). Repeat color Doppler ultrasonography of the bilateral iliac and lower extremity arteries showed patent bilateral iliac arteries; the common femoral, superficial femoral, deep femoral, popliteal, posterior tibial, and peroneal arteries demonstrated localized intimal irregularity with hyperechoic plaques attached to the vessel walls, without focal stenosis or dilation. The skin biopsy pathological section showed characteristic findings (Fig 2, C). Clinical photographs of bilateral feet. A, Blue toe syndrome showing toe cyanosis and ischemic changes. B, Reticular livedo changes on bilateral lower extremity skin. C, Skin biopsy pathological section showing characteristic findings. Given inadequate peripheral circulation improvement, beraprost sodium 40 μg was added orally three times daily. Two days later, the patient developed abdominal distension and pain with bloody stools appearing dark brown. The fecal occult blood test was positive. Gastrointestinal bleeding was suspected, and the patient was readmitted. Given the patient's aspirin enteric-coated tablets and clopidogrel use, combined with the recent addition of beraprost sodium, nonsteroidal anti-inflammatory drug-related peptic ulcer bleeding was considered. Aspirin enteric-coated tablets were discontinued, and lansoprazole enteric-coated tablets were prescribed for gastric acid suppression, along with sucralfate suspension for gastric mucosal protection. Stool color gradually normalized, and fecal occult blood became weakly positive. A complete blood count showed an eosinophil count of 2.64 × 109/L (ratio, 16.2%). Liver function tests revealed alanine aminotransferase 170 U/L, aspartate aminotransferase 105 U/L, gamma-glutamyl transferase 223 U/L, and alkaline phosphatase 328 U/L. Renal function showed serum urea at 15.77 mmol/L, creatinine at 213.2 μmol/L, and eGFR at 27.9 mL/min/1.73 m2. Cardiac markers showed myoglobin 146 μg/L, N-terminal pro–B-type natriuretic peptide 12,403 ng/L, and high-sensitivity cardiac troponin T 127 ng/L. Coagulation studies showed D-dimer 2.28 mg/L, thrombomodulin 16.6 TU/ml, and thrombin-antithrombin complex 4.8 ng/ml. Radionuclide renal dynamic imaging with technetium Tc 99m diethylenetriamine pentaacetate revealed severe impairment of left renal filtration function. The left kidney GFR was only 5.28 mL/min, accounting for merely 23.2% of the total split renal function. The corresponding time-activity curve of the left kidney showed no functional plateau, indicating near-complete loss of glomerular filtration capacity. The right kidney demonstrated compensatory changes with a GFR of 17.4 mL/min, accounting for 76.8% of the split function. However, the total GFR was only 22.7 mL/min, confirming that the right kidney also had reduced function and was unable to fully compensate for the left renal injury. Overall, the patient had severe renal insufficiency with a total GFR of 22.7 mL/min, consistent with chronic kidney disease (CKD) stage 4. Bilateral renal function was significantly impaired, with the left kidney being the most severely affected (Fig 3). Technetium Tc 99m diethylenetriamine pentaacetate (99mTc-DTPA) renal dynamic imaging + glomerular filtration rate (GFR). BSA, Body surface area. The patient exhibited somnolence with normal limb muscle strength and no pathological neurological signs. Cranial magnetic resonance imaging (MRI) showed acute lacunar cerebral infarction in the left thalamus (Fig 4, A), lacunar encephalomalacia in the pons, right thalamus, and left basal ganglia, white matter hyperintensity (Fazekas grade 1), and brain atrophy (Fig 4, B). Cranial magnetic resonance imaging (MRI) examination. A, Diffusion-weighted imaging showing acute lacunar cerebral infarction in the left thalamus (red arrow). B, T2-weighted fluid-attenuated inversion recovery sequence showing white matter hyperintensity, Fazekas grade 1. The patient recently developed blurred vision and photophobia. Fundoscopic examination revealed a cherry-red spot at the macula (Fig 5): cholesterol emboli affected the small arteries supplying the macula; the fovea appeared distinctly red because of the contrast with surrounding retinal edema, where choroidal capillary blood appears more prominent, forming the characteristic cherry-red spot. Combined with the patient's clinical manifestations and auxiliary examination results, a diagnosis of CES was established. Fundoscopic examination: revealing a cherry-red spot at the macula characteristic of cholesterol embolization. L, Left; R, right. The patient was followed up in our outpatient clinic for 3 months postdischarge. At the 1-month follow-up, serum creatinine had improved to 156.8 μmol/L with an eGFR of 38.2 mL/min/1.73 m2. At the 2-month follow-up, serum creatinine was 142.3 μmol/L with an eGFR of 42.5 mL/min/1.73 m2. At the 3-month follow-up, serum creatinine stabilized at 138.5 μmol/L with eGFR of 44.1 mL/min/1.73 m2, indicating CKD stage 3b (improved from stage 4 at presentation). Following the diagnosis of CES, statin therapy was intensified from rosuvastatin 10 mg to 20 mg daily for plaque stabilization and prevention of further cholesterol crystal embolization. The patient remained on long-term statin therapy (rosuvastatin 20 mg daily) and antiplatelet therapy (clopidogrel 75 mg daily). No further episodes of CES or renal function deterioration were observed during the follow-up period. Discussion Pathogenesis and pathophysiology The pathogenesis of CES involves multiple mechanisms. First, cholesterol crystals within atherosclerotic plaques become dislodged under specific triggering conditions. These triggering factors include vascular interventional procedures (such as iliac artery balloon angioplasty, mechanical atherectomy, and stent placement as performed in this patient), anticoagulation or thrombolytic therapy, arterial trauma, and natural plaque rupture. The literature reports that CES occurs in approximately 1% to 5% of patients following vascular interventional procedures, with aortic manipulation carrying the highest risk.1 Dislodged cholesterol crystals travel distally and occlude small arteries with diameters of 100 to 200 μm. The crystals themselves and their induced inflammatory response cause vascular endothelial damage, smooth muscle proliferation, and fibrin thrombus formation, creating a “garbage-collector effect” that amplifies the embolic range. Cholesterol crystals also activate the complement system, promoting eosinophil infiltration, which explains the marked eosinophilia observed in this patient. The onset of symptoms 1 week after an aortic interventional procedure in this patient conforms to the typical temporal window of CES (days to weeks postprocedure). Surgical manipulation caused rupture of atherosclerotic plaques, with cholesterol crystals embolizing to the microvasculature of multiple target organs. The use of mechanical atherectomy in this case likely contributed to plaque destabilization and cholesterol crystal release, consistent with the known risk of CES after endovascular procedures in patients with shaggy aortas. Blue toe syndrome indicates lower extremity small artery embolization; reticular livedo reflects cutaneous microcirculatory dysfunction; gastrointestinal bleeding may result from mesenteric artery embolization or stress ulceration; and acute kidney injury reflects renal microvascular involvement. Clinical manifestations CES presents with diverse clinical manifestations affecting multiple organ systems. This patient demonstrated typical multiorgan involvement. Cutaneous manifestations are the most common and characteristic findings. Blue toe syndrome is the classic presentation of CES, presenting with toe pain, cyanosis, and gangrene, whereas dorsalis pedis and posterior tibial pulses are often preserved.2 The blue toe syndrome and reticular livedo observed in this patient strongly suggest cutaneous microvascular embolization. The literature reports that approximately 30% to 50% of CES patients develop cutaneous manifestations, including reticular livedo, purpura, ulceration, and digital gangrene. The kidneys are among the most frequently involved organs in CES. Approximately 50% of CES patients develop acute or subacute renal impairment, ranging from mild eGFR decline to acute renal failure requiring dialysis.3 This patient's creatinine increased to 213.2 μmol/L with eGFR declining to 27.9 mL/min/1.73 m2, indicating moderate-to-severe renal impairment. However, with conservative management, his renal function partially recovered over 3 months to CKD stage 3b, demonstrating that some renal recovery is possible with early diagnosis and supportive care. The patient remains under ongoing follow-up. Mechanisms of renal damage include direct embolization of renal arterioles by cholesterol crystals, renin-angiotensin system activation, and increased endothelin release. The somnolence and acute lacunar cerebral infarction on cranial MRI in this patient indicate central nervous system involvement. CES-related cerebral infarction is predominantly lacunar, located in deep gray matter structures, such as the lentiform nucleus, thalamus, and pons, consistent with the anatomical distribution of small perforating artery embolization. Elevated eosinophil count is an important laboratory finding in CES, observed in approximately 50% to 80% of patients, and serves as a valuable diagnostic clue.4 Fundoscopic examination is an important diagnostic tool for CES. This patient's fundoscopy revealed a cherry-red spot at the macula, a characteristic finding of cholesterol embolization. The mechanism involves cholesterol crystal embolization of retinal small arteries, causing retinal edema, whereas the fovea appears cherry red because of the absence of photoreceptor cells. This finding is of significant value for confirming CES diagnosis. The literature reports ocular involvement in approximately 25% of CES patients, including cotton-wool spots and retinal artery occlusion in addition to cherry-red spots.5 Diagnostic criteria CES diagnosis is based on comprehensive analysis of clinical presentations, laboratory investigations, and imaging studies. This patient met the following diagnostic criteria: (1) Precipitating factors: recent history of aortic interventional procedure with mechanical atherectomy and stent placement; (2) typical clinical manifestations: blue toe syndrome, reticular livedo, and multiorgan dysfunction; (3) laboratory findings: marked eosinophilia with hepatic and renal dysfunction and elevated cardiac markers; (4) imaging studies: cranial MRI showing acute lacunar infarction and fundoscopy revealing cherry-red spot. The presence of these features essentially confirms CES diagnosis. The gold standard for definitive diagnosis is tissue biopsy demonstrating cholesterol crystals. Skin, kidney, or gastrointestinal biopsy may reveal characteristic cholesterol crystals (appearing as rhomboid or needle-shaped clefts) within affected small arteries. However, because of the invasiveness of biopsy and its false-negative rate, clinical diagnosis is typically based on characteristic clinical presentations in practice. Among laboratory findings, eosinophilia, elevated erythrocyte sedimentation rate, and hypocomplementemia are common in CES but lack specificity. Imaging studies primarily serve to assess the extent of target organ damage and exclude other conditions. Differential diagnosis CES requires differentiation from the following conditions: (1) thrombotic microangiopathies, including hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, which may also present with multiorgan dysfunction and microangiopathic hemolytic anemia, but peripheral blood shows schistocytes and decreased activity of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13. (2) Vasculitis: including polyarteritis nodosa and antineutrophil cytoplasmic antibody-associated vasculitis, which may involve multiple organs but is usually present with autoantibody positivity (antineutrophil cytoplasmic antibody, antineutrophil cytoplasmic antibodies, etc), and biopsy shows inflammatory cell infiltration in vessel walls rather than cholesterol crystals. (3) Cardioembolic stroke: patients with embolic risk factors such as atrial fibrillation and left ventricular mural thrombus; cerebral infarction is typically cortical or larger territory rather than lacunar. (4) Infectious endocarditis: may present with multiorgan embolization but usually accompanied by fever, positive blood cultures, and cardiac murmurs; peripheral blood shows neutrophilia rather than eosinophilia. Literature review A systematic review of the available literature on CES reveals several important themes. First, the incidence of CES following endovascular procedures is reported to be 1% to 5% in most series, with aortic and renal artery interventions carrying the highest risk.6, 7, 8 Fine et al9 reported one of the largest case series of 221 patients, identifying vascular surgery and angiography as the most common precipitating factors. Kronzon and Saric6 specifically addressed CES after cardiovascular surgery and interventions, noting that the risk is highest in patients with extensive aortic atherosclerosis (shaggy aorta) and those undergoing complex endovascular procedures involving multiple manipulations. Risk factors for CES development have been identified in multiple studies. Patient-level factors include advanced age (>70 years), male sex, hypertension, diabetes mellitus, smoking, and pre-existing renal dysfunction. Procedural factors include the use of large-bore sheaths, prolonged procedure time, multiple catheter exchanges, and atherectomy or other plaque-modifying techniques.6,8,10 Stacy et al8 reported a case of CES after endovascular aortic aneurysm repair, emphasizing the risk of manipulating a heavily diseased aorta. Tanaka et al11 highlighted the risk of CES after anticoagulant therapy, which may promote plaque hemorrhage and cholesterol crystal release. Scolari et al12 emphasized the diagnostic challenge of atheroembolic renal disease, identifying key clinical features and prognostic factors that aid in early recognition. Clinical presentation patterns from published case series consistently demonstrate multiorgan involvement. Cutaneous manifestations (blue toe syndrome, livedo reticularis) are present in 30% to 50% of cases.7,10 Renal involvement occurs in approximately 50% of patients and is a major determinant of prognosis.13,14 Cerebral involvement, typically presenting as lacunar infarction, is reported in 15% to 25% of cases.15 Ocular findings, including cherry-red spots and cotton-wool spots, are present in approximately 25% of patients.16,17 Eosinophilia, observed in 50% to 80% of cases, remains one of the most valuable laboratory clues.18 Diagnostic approaches described in the literature emphasize the importance of a high index of suspicion in patients with recent vascular intervention or anticoagulation who develop multiorgan dysfunction. While tissue biopsy demonstrating cholesterol crystals remains the gold standard, the sensitivity is limited by sampling error and the invasiveness of the procedure. Clinical diagnosis based on characteristic findings is therefore accepted in practice. Imaging studies (computed tomography angiography, MRI, and fundoscopy) serve to assess the extent of target organ damage and support the diagnosis. Treatment strategies and outcomes have been reported in multiple observational studies. Supportive care, including discontinuation of anticoagulation and hydration, remains the cornerstone of management. The role of corticosteroids remains controversial: Fabbian et al19 reported potential benefit with corticosteroid therapy, whereas Belenfant et al13 demonstrated that supportive treatment alone improved survival in multivisceral CES. Statins are widely recommended for plaque stabilization and prevention of recurrence.20 Prognosis depends heavily on the extent of renal involvement; mortality rates range from 25% to 50%, with acute renal failure, infection, and cardiovascular events as the leading causes of death.7,13 This case contributes to the existing literature by highlighting several important points: (1) CES can occur even after localized aortoiliac intervention without thoracic or paravisceral aortic manipulation; (2) the use of mechanical atherectomy in patients with extensive aortic atherosclerosis may increase the risk of CES; (3) partial renal recovery is possible with conservative management over 3 months, with ongoing follow-up planned; (4) the combination of blue toe syndrome, eosinophilia, and cherry-red spot on fundoscopy provides a highly characteristic clinical picture that can facilitate early diagnosis without the need for invasive tissue biopsy. Treatment and prognosis Treatment principles for CES include eliminating precipitating factors, supportive care, and preventing complications. Following diagnosis, this patient immediately discontinued medications that may have exacerbated embolization and received appropriate supportive treatment. The role of glucocorticoids in CES treatment remains controversial. Some studies demonstrate that early glucocorticoid use may improve symptoms and reduce mortality, particularly in severe cases involving the kidneys and skin. However, other studies suggest that glucocorticoids do not alter disease progression and may increase infection risk. This patient did not receive glucocorticoids, and his condition stabilized with supportive care. Statins are an important component of CES management, as they may prevent disease progression and recurrence by stabilizing atherosclerotic plaques and lowering cholesterol levels. This patient had a clear history of atherosclerosis and should receive long-term statin therapy postprocedure. Antiplatelet agents such as aspirin and clopidogrel require careful weighing of bleeding risk against thrombotic prevention; this patient discontinued aspirin following gastrointestinal bleeding. The prognosis of CES depends on the number of involved organs and the degree of functional impairment. The literature reports mortality rates of 25% to 50%, with major causes of death being acute renal failure, infection, and cardiovascular events. Age greater than 70 years, elevated serum creatinine, and congestive heart failure are poor prognostic factors. Although this patient's disease involved multiple organs, his relatively stable condition following timely diagnosis and aggressive treatment, with partial renal recovery over 3 months (with ongoing follow-up), demonstrates the importance of early diagnosis for improving prognosis. Conclusions This case demonstrates the typical clinical features of CES, including onset following aortic interventional procedure with mechanical atherectomy, blue toe syndrome and reticular livedo as cutaneous manifestations, multiorgan dysfunction (involving kidneys, liver, heart, and brain), marked eosinophilia, and a characteristic fundoscopic cherry-red spot. This case suggests that for patients with a history of atherosclerosis who have recently undergone vascular interventional procedures, the appearance of blue toe syndrome, reticular livedo with eosinophilia, and multiorgan dysfunction should raise high suspicion for CES. Early diagnosis, prompt discontinuation of precipitating medications, and aggressive supportive care are key to improving prognosis. The 3-month follow-up demonstrates that partial renal recovery is possible with conservative management, and the patient remains under ongoing follow-up. This contributes to the limited long-term outcome data available in the literature. Funding None. Disclosures None. Footnotes The editors and reviewers of this article have no relevant financial relationships to disclose per the Journal Policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest. References